The Recombinant Human IFN-α2b Protein manufactured by Seafrom is suitable for antiviral and immunomodulatory effects. Human IFN-α2a and -α2b are allelic variants of the same gene. IFN-α2a and -α2b differ in their mature protein sequences by 23 amino acids, which consist of aspartic acid and arginine residues. They are the only IFN-α subtypes in humans that have O-glycosylation sites. Human IFN-α2b can be induced by co-culturing with CpG oligonucleotides or loxoribine in peripheral blood mononuclear cells (PBMCs) and plasma dendritic-like cells. IFN-α subtypes are classified as intermediate to strong inducers of ISGs (Interferon Stimulated Genes) and exhibit potent antiviral activity against influenza A viruses. Similar to IFN-α1 and IFN-α8 subtypes, human IFN-α2 is expressed early after Sendai virus infection in vitro and may transmit the "start" signal to neighboring cells regardless of the diversity of virus infection (MOI). Recombinant human IFN-α2 is the only clinically approved subtype, and both IFN-α2a and IFN-α2b are used for the treatment of chronic hepatitis B or C, hairy cell leukemia, and other forms of cancer. The lyophilized product can be stored at 4°C for 24 months, and the reconstituted liquid can be stored at -20°C for 6-12 months, avoiding repeated freeze-thaw cycles.